Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Phibro Animal Health Corporation is a drug manufacturers-specialty & generic business based in the US. Phibro Animal Health Corporation shares (PAHC) are listed on the NASDAQ and all prices are listed in US Dollars. Phibro Animal Health Corporation employs 1,725 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $19.57 |
|---|---|
| 52-week range | $18.63 - $30.68 |
| 50-day moving average | $20.70 |
| 200-day moving average | $23.85 |
| Wall St. target price | $21.00 |
| PE ratio | 16.6667 |
| Dividend yield | $0.48 (2.41%) |
| Earnings per share (TTM) | $1.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.57 from 2022-01-25
| 1 week (2022-01-16) | N/A |
|---|---|
| 1 month (2021-12-23) | -5.55% |
| 3 months (2021-10-27) | -10.80% |
| 6 months (2021-07-27) | -18.76% |
| 1 year (2021-01-27) | -6.68% |
|---|---|
| 2 years (2020-01-27) | -21.22% |
| 3 years (2019-01-25) | 31.65 |
| 5 years (2017-01-27) | 27.15 |
Valuing Phibro Animal Health Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Phibro Animal Health Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Phibro Animal Health Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Phibro Animal Health Corporation shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Phibro Animal Health Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6618. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Phibro Animal Health Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Phibro Animal Health Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $104.2 million.
The EBITDA is a measure of a Phibro Animal Health Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $852.8 million |
|---|---|
| Operating margin TTM | 8.65% |
| Gross profit TTM | $271.4 million |
| Return on assets TTM | 5.67% |
| Return on equity TTM | 22.84% |
| Profit margin | 5.7% |
| Book value | $5.76 |
| Market capitalisation | $810.1 million |
TTM: trailing 12 months
Dividend payout ratio: 38.4% of net profits
Recently Phibro Animal Health Corporation has paid out, on average, around 38.4% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.41% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Phibro Animal Health Corporation shareholders could enjoy a 2.41% return on their shares, in the form of dividend payments. In Phibro Animal Health Corporation's case, that would currently equate to about $0.48 per share.
While Phibro Animal Health Corporation's payout ratio might seem fairly standard, it's worth remembering that Phibro Animal Health Corporation may be investing much of the rest of its net profits in future growth.
Phibro Animal Health Corporation's most recent dividend payout was on 14 December 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 November 2021 (the "ex-dividend date").
Over the last 12 months, Phibro Animal Health Corporation's shares have ranged in value from as little as $18.628 up to $30.6769. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Phibro Animal Health Corporation's is 0.5773. This would suggest that Phibro Animal Health Corporation's shares are less volatile than average (for this exchange).
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.